Print
Email
Print Edition Stories
Quanterix Corp. of Cambridge has won a contract from the Department of Homeland Security to develop a test for the botulinum toxin that would be sensitive enough to find a single molecule in a sample.
According to a release from the company, Quanterix was awarded a one-year $250,155 contract under which it will work with the Botulinum Research Center at the University of Massachusetts Dartmouth to apply Quanterix’s Single Molecule Array technology in a test that would be 1,000 times more sensitive than current assays.
DHS official David Hodge said in the release that the technology from Quanterix would help “address a number of challenges currently faced by DHS for identifying active agents of bioterrorism.”
The contract comes a few months after Quanterix named former Millipore Corp. CEO Martin Madaus the new permanent CEO of Quanterix. Madaus had been serving as acting CEO at Quanterix since June and had been serving as chairman since last October.
Founded in 2007, Quanterix has received $26 million in two rounds of financing, most recently taking in August $6 million of an open-ended funding round. Investors include Bain Capital Ventures of Boston, Flagship Ventures of Cambridge and ARCH Venture Partners of Chicago. The board at Quanterix includes Flagship Ventures general partner Douglas Cole and Bain Capital Ventures managing director James Nahirny.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
